This treatment paradigm is aimed at mitigating the consequences of VEGF signaling, mainly macular edema and angiogenesis; however, it has limited potential to modify the underlying key triggers of VEGF production, such as retinal ischemia [3]. The gene discussed is VEGFA; the disease is retinal ischemia.